Literature DB >> 12527323

Anthrax toxin receptor proteins.

Kenneth A Bradley1, John A T Young.   

Abstract

Anthrax toxin is a key virulence factor for Bacillus anthracis, the causative agent of anthrax. Here we discuss what is known about the anthrax toxin receptor (ATR), the cellular receptor for anthrax toxin, and how this information is being used to develop treatments for anthrax as well as to understand aspects of cancer. ATR was identified recently as a type I transmembrane protein with unknown function that contains an extracellular integrin-like inserted (I) domain. The ATR I domain contains the toxin binding site, and a soluble form of this domain was shown to serve as an effective antitoxin to protect cultured cells from toxin action. ATR is encoded by the tumor endothelial marker 8 (TEM8) gene, which is selectively up-regulated during blood vessel formation and in tumor vasculature, raising the possibility that this protein normally functions in angiogenesis. Therefore, identification of the cellular receptor for anthrax toxin has made possible new avenues of research in the areas of anthrax pathogenesis, antitoxin development, and cancer biology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527323     DOI: 10.1016/s0006-2952(02)01455-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  The cytoplasmic domain of anthrax toxin receptor 1 affects binding of the protective antigen.

Authors:  Mandy Y Go; Edith M C Chow; Jeremy Mogridge
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

Review 2.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

3.  Neutralization of B. anthracis toxins during ex vivo phagocytosis.

Authors:  Olga Tarasenko; Ashley Scott; April Jones; Lee Soderberg; Pierre Alusta
Journal:  Glycoconj J       Date:  2012-09-15       Impact factor: 2.916

4.  A non-classical assembly pathway of Escherichia coli pore-forming toxin cytolysin A.

Authors:  Monifa Fahie; Fabian B Romano; Christina Chisholm; Alejandro P Heuck; Mark Zbinden; Min Chen
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

5.  Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Authors:  Xiangyang Chi; Jianmin Li; Weicen Liu; Xiaolin Wang; Kexin Yin; Ju Liu; Xiaodong Zai; Liangliang Li; Xiaohong Song; Jun Zhang; Xiaopeng Zhang; Ying Yin; Ling Fu; Junjie Xu; Changming Yu; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

6.  Glycoconjugates prevent B. anthracis toxin-induced cell death through binding while activating macrophages.

Authors:  Olga Tarasenko; Ashley Scott; Lee Soderberg; Pierre Alusta
Journal:  Glycoconj J       Date:  2011-12-02       Impact factor: 2.916

7.  Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore.

Authors:  Qingfu Xu; Eric D Hesek; Mingtao Zeng
Journal:  Microb Pathog       Date:  2007-03-15       Impact factor: 3.738

8.  Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Authors:  Cassandra D Kelly-Cirino; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

9.  Targeted silencing of anthrax toxin receptors protects against anthrax toxins.

Authors:  Maria T Arévalo; Ashley Navarro; Chenoa D Arico; Junwei Li; Omar Alkhatib; Shan Chen; Diana Diaz-Arévalo; Mingtao Zeng
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

Review 10.  Receptors of anthrax toxin and cell entry.

Authors:  Gisou van der Goot; John A T Young
Journal:  Mol Aspects Med       Date:  2009-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.